These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 19553788)

  • 21. Supplement on combination therapy.
    Brucker AJ; Spaide R
    Retina; 2009 Jun; 29(6 Suppl):S1. PubMed ID: 19553787
    [No Abstract]   [Full Text] [Related]  

  • 22. [Electroretinography in the diagnosis and monitoring of treatment for neovascular age-related macular degeneration: Communication 2].
    Zueva MV; Tsapenko IV; Riabina MV; Grinchenko MI; Neroeva NV
    Vestn Oftalmol; 2009; 125(4):55-9. PubMed ID: 19824452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment for wet macular degeneration.
    FDA Consum; 2006; 40(5):6. PubMed ID: 17326303
    [No Abstract]   [Full Text] [Related]  

  • 25. Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.
    Nat Rev Drug Discov; 2009 Dec; 8(12):922. PubMed ID: 19949394
    [No Abstract]   [Full Text] [Related]  

  • 26. Intravitreal triamcinolone acetonide preceding photodynamic therapy for exudative age-related macular degeneration.
    Roth DB; Kulkarni KM; Walsman S; Modi A
    Ophthalmic Surg Lasers Imaging; 2009; 40(5):467-71. PubMed ID: 19772270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Polypoidal choroidal vasculopathy--a rare form of choroidal neovascularization].
    Weglarz M; Karska-Basta I; Kubicka-Trzaska A; Romanowska-Dixon B
    Klin Oczna; 2009; 111(4-6):145-8. PubMed ID: 19673446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Companies eye slice of age-related macular degeneration market.
    Waltz E
    Nat Biotechnol; 2006 Sep; 24(9):1041-2. PubMed ID: 16964195
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of sclerotic macular dystrophy].
    Smidovich LE
    Oftalmol Zh; 1978; (6):471. PubMed ID: 714359
    [No Abstract]   [Full Text] [Related]  

  • 30. The use of intraocular corticosteroids.
    Kiernan DF; Mieler WF
    Expert Opin Pharmacother; 2009 Oct; 10(15):2511-25. PubMed ID: 19761356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
    Shah AR; Del Priore LV
    Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring ocular drug therapy by analysis of aqueous samples.
    Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
    Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Researchers study new treatment for macular degeneration.
    Mayo Clin Health Lett; 2012 May; 30(5):4. PubMed ID: 22754958
    [No Abstract]   [Full Text] [Related]  

  • 34. [Electroretinography in the diagnosis and monitoring of treatment for neovascular age-related macular degeneration: Communication 1].
    Zueva MV; Tsapenko IV; Riabina MV; Grinchenko MI; Neroeva NV
    Vestn Oftalmol; 2009; 125(4):51-4. PubMed ID: 19824451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sight drug deal ends High Court challenge.
    Dyer C
    BMJ; 2008 Jul; 337():a1039. PubMed ID: 18658188
    [No Abstract]   [Full Text] [Related]  

  • 36. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future of cosmeceuticals: an interview with Albert Kligman, MD, PhD. Interview by Zoe Diana Draelos.
    Kligman A
    Dermatol Surg; 2005 Jul; 31(7 Pt 2):890-1. PubMed ID: 16029684
    [No Abstract]   [Full Text] [Related]  

  • 38. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.
    Jahn EM; Schneider CK
    N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of multiaccess infusion devices on in vitro drug delivery during multi-infusion therapy.
    Décaudin B; Dewulf S; Lannoy D; Simon N; Secq A; Barthélémy C; Debaene B; Odou P
    Anesth Analg; 2009 Oct; 109(4):1147-55. PubMed ID: 19762742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verteporfin: restriction of indications: labelling change. A welcome move. A negative risk-benefit balance in neovascular forms of ARMD with "occult" lesions.
    Prescrire Int; 2008 Oct; 17(97):192. PubMed ID: 19536923
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.